EICHORCondition: Advanced Solid Tumor · Sponsor: Exelixis
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Exelixis Clinical Trials · 1-888-393-5494) · druginfo@exelixis.com
Always discuss trial participation with your own doctor first.
| Exelixis Clinical Site #12 | Fountain Valley, California, United States | Withdrawn |
| Exelixis Clinical Site #15 | Jacksonville, Florida, United States | Recruiting |
| Exelixis Clinical Site #8 | Orlando, Florida, United States | Recruiting |
| Exelixis Clinical Site #16 | Tampa, Florida, United States | Recruiting |
| Exelixis Clinical Site #14 | Rochester, Minnesota, United States | Recruiting |
| Exelixis Clinical Site #10 | Kansas City, Missouri, United States | Withdrawn |
| Exelixis Clinical Site #9 | New Brunswick, New Jersey, United States | Recruiting |
| Exelixis Clinical Site #5 | New York, New York, United States | Recruiting |
| Exelixis Clinical Site #7 | Cleveland, Ohio, United States | Recruiting |
| Exelixis Clinical Site #13 | Oklahoma City, Oklahoma, United States | Recruiting |
| Exelixis Clinical Site #11 | Germantown, Tennessee, United States | Recruiting |
| Exelixis Clinical Site #6 | Nashville, Tennessee, United States | Recruiting |
+ 4 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05932862